Quantinno Capital Management LP Purchases 7,850 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Quantinno Capital Management LP lifted its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 43.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,909 shares of the medical research company's stock after buying an additional 7,850 shares during the period. Quantinno Capital Management LP's holdings in IQVIA were worth $5,092,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mufg Securities Americas Inc. acquired a new stake in shares of IQVIA in the 4th quarter valued at $500,000. Malaga Cove Capital LLC increased its holdings in shares of IQVIA by 77.9% during the fourth quarter. Malaga Cove Capital LLC now owns 2,442 shares of the medical research company's stock worth $480,000 after buying an additional 1,069 shares in the last quarter. Nomura Holdings Inc. bought a new position in shares of IQVIA in the fourth quarter valued at approximately $1,117,000. NorthRock Partners LLC bought a new stake in IQVIA during the 4th quarter worth approximately $397,000. Finally, OMERS ADMINISTRATION Corp raised its position in IQVIA by 20.2% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 7,595 shares of the medical research company's stock valued at $1,492,000 after purchasing an additional 1,276 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 0.9%

NYSE IQV traded up $1.36 during trading on Tuesday, hitting $144.90. The stock had a trading volume of 4,613,523 shares, compared to its average volume of 1,536,363. The company has a market capitalization of $25.07 billion, a PE ratio of 19.32, a P/E/G ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The company's 50-day moving average price is $158.99 and its two-hundred day moving average price is $185.26. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter last year, the firm earned $2.54 earnings per share. The firm's revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IQV. Morgan Stanley boosted their price objective on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. HSBC lowered IQVIA from a "buy" rating to a "hold" rating and cut their price target for the company from $260.00 to $160.00 in a research note on Friday, April 25th. UBS Group lowered their price objective on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $228.14.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.